​Wave Life Sciences has announced encouraging interim results from its Phase 2 FORWARD-53 clinical trial of WVE-N531, an exon skipping oligonucleotide being investigated for the treatment of individuals with Duchenne who are amenable to exon 53 skipping. According to Wave, FORWARD-53 achieved all trial goals, demonstrating sustained exon skipping, muscle concentrations, and dystrophin restoration through 48 weeks. 

Results demonstrate decreases in inflammation and necrosis, a statistically significant reversal of muscle fibrosis, and a transition from regeneration to maturation of muscle. Additionally, data shows a 50% decline in creatine kinase and functional improvements observed in Time-to-Rise, North Star Ambulatory Assessment, and hand grip strength. WVE-N531 was also safe and well-tolerated through 48 weeks. Finally, data collected on the product’s half-life, a measure of how long a drug stays in the body, supports moving to monthly dosing of WVE-N531.

Wave indicated that the company met with the U.S. Food and Drug Administration (FDA) on WVE-N531 to discuss its interim 24-week data and initial plans for the confirmatory trial. According to Wave, the FDA confirmed that the accelerated approval pathway using dystrophin expression as a surrogate endpoint remains open. Based on the FDA feedback and the 48-week data, Wave intends to file a New Drug Application (NDA) in 2026 for accelerated approval of WVE-N531, based on all FORWARD-53 data.

Read Wave’s press release here.

Read Wave’s community letter here.